[{"orgOrder":0,"company":"Pretzel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PX578","moa":"POLG","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pretzel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pretzel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pretzel Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Pretzel Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          China Battery Fair
                          Not Confirmed
                          China Battery Fair
                          Not Confirmed

                          Details : PX578, the lead therapeutic in Pretzel’s bioenergetics restoration franchise, represents a first-in-class approach to targeting mitochondrial DNA polymerase across MDDS.

                          Product Name : PX578

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 03, 2025

                          Lead Product(s) : PX578

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank